Natco Pharma, 524816, NATCOPHARM Share Price, Rating, Research, Analysis, Fundamental & Historical Data

Stock Summary

Market Cap(Crs)
Stock P:E
Face Value

16,690.35
11.77
2

Enterprise Value(Crs)
Dividend Yield
Price:Book Value

15,845.85
0.54%
1.81

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

10 Years
5 Years
3 Years

15.57
16.64
17.84

EBITDA CAGR (%)

10 Years
5 Years
3 Years

23.51
29.44
19.20

PAT CAGR (%)

10 Years
5 Years
3 Years

28.39
33.73
38.14

P:E (Median)

8 Years
5 Years
3 Years

18.11
15.79
12.57

P:BV (Average)

8 Years
5 Years
3 Years

3.11
2.84
2.70

EV:EBITDA (Average)

8 Years
5 Years
3 Years

15.32
14.88
8.77

Earnings Forecasts:

(Updated: 27-06-2026)

Description 2026 2027 2028 2029
Adj EPS -20.04 73.62 39.93 47.07
P/E Ratio -46.47 12.65 23.32 19.79
Revenue 17.01 4070.12 3083.84 3544.57
EBITDA 3245.9 1490.2 723.01 857.89
Net Income 1014.67 1304.48 708.71 894.27
ROA 956.33 13.92 6.18 6.83
P/B Ratio -0.30 1.90 1.74 1.62
ROE 1.44 15.75 7.65 8.36
FCFF 8.8 637.69 693.49 326.69
FCFF Yield 1742.58 4.42 4.81 2.27
Net Debt 12.08 -2484.7 -2606.67 -2946.07
BVPS -3150.5 489.13 535.86 574.54

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone

Description Mar 26 Mar 25 Var% Dec 25 Dec 24 Var% Sep 25 Sep 24 Var% Jun 25 Jun 24 Var%
Net Sales 608.80 1,157.40 -47.40% 528.80 407.60 29.74% 1,264.30 1,292.60 -2.19% 1,192.70 1,236.90 -3.57%
Expenses 516.40 596.20 -13.38% 408.50 378.20 8.01% 711.80 501.90 41.82% 653.00 473.90 37.79%
EBITDA 92.40 561.20 -83.54% 120.30 29.40 309.18% 552.50 790.70 -30.13% 539.70 763.00 -29.27%
EBIDTM 15.18% 48.49% 22.75% 7.21% 43.70% 61.17% 45.25% 61.69%
Other Income 72.90 62.10 17.39% 55.30 168.00 -67.08% 93.30 51.40 81.52% 59.60 39.80 49.75%
Interest 9.70 8.80 10.23% 8.30 3.40 144.12% 11.70 3.00 290.00% 2.60 4.40 -40.91%
Depreciation 45.60 93.70 -51.33% 42.10 43.70 -3.66% 48.10 42.20 13.98% 53.80 40.40 33.17%
PBT 110.00 520.80 -78.88% 125.20 150.30 -16.70% 586.00 796.90 -26.47% 542.90 758.00 -28.38%
Tax -99.60 92.70 - 18.30 25.40 -27.95% 85.10 135.80 -37.33% 78.80 121.70 -35.25%
PAT 209.60 428.10 -51.04% 106.90 124.90 -14.41% 500.90 661.10 -24.23% 464.10 636.30 -27.06%
PATM 34.43% 36.99% 20.22% 30.64% 39.62% 51.15% 38.91% 51.44%
EPS 11.70 23.90 -51.05% 5.97 6.97 -14.35% 27.97 36.91 -24.22% 25.91 35.53 -27.08%

Description Mar 26 Mar 25 Var% Dec 25 Dec 24 Var% Sep 25 Sep 24 Var% Jun 25 Jun 24 Var%
Net Sales 739.10 1,221.00 -39.47% 647.30 474.80 36.33% 1,363.00 1,371.10 -0.59% 1,328.90 1,362.60 -2.47%
Expenses 611.50 672.90 -9.12% 488.60 436.00 12.06% 783.80 566.80 38.29% 757.90 557.80 35.87%
EBITDA 127.60 548.10 -76.72% 158.70 38.80 309.02% 579.20 804.30 -27.99% 571.00 804.80 -29.05%
EBIDTM 17.26% 44.89% 24.52% 8.17% 42.49% 58.66% 42.97% 59.06%
Other Income 77.80 66.30 17.35% 58.10 176.30 -67.04% 100.00 63.80 56.74% 61.70 48.10 28.27%
Interest 10.90 10.20 6.86% 9.50 4.40 115.91% 13.10 4.10 219.51% 3.20 5.20 -38.46%
Depreciation 50.40 98.30 -48.73% 46.20 47.00 -1.70% 52.40 45.80 14.41% 57.60 44.10 30.61%
PBT 144.10 505.90 -71.52% 161.10 163.70 -1.59% 613.70 818.20 -24.99% 571.90 803.60 -28.83%
Tax -89.20 99.90 - 20.70 31.30 -33.87% 95.80 141.70 -32.39% 91.60 135.10 -32.20%
PAT 233.30 406.00 -42.54% 140.40 132.40 6.04% 517.90 676.50 -23.44% 480.30 668.50 -28.15%
PATM 31.57% 33.25% 21.69% 27.89% 38.00% 49.34% 36.14% 49.06%
EPS 14.97 22.72 -34.11% 8.46 7.43 13.86% 28.96 37.84 -23.47% 26.85 37.35 -28.11%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone

Description TTM Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Net Sales 3,594.60 4,094.50 3,568.90 2,351.00 1,767.80 1,653.50 1,790.20 1,986.30 2,091.30 1,958.00 1,021.40 Net Sales Growth -12.21% 14.73% 51.80% 32.99% 6.91% -7.64% -9.87% -5.02% 6.81% 91.70% Cost Of Goods Sold 573.70 545.00 525.80 485.60 502.10 472.30 369.80 317.60 388.50 572.80 256.30 Gross Profit 3,020.90 3,549.50 3,043.10 1,865.40 1,265.70 1,181.20 1,420.40 1,668.70 1,702.80 1,385.20 765.10 GP Margin 84.04% 86.69% 85.27% 79.34% 71.60% 71.44% 79.34% 84.01% 81.42% 70.75% 74.91% Total Expenditure 2,289.70 1,952.40 1,931.90 1,530.20 1,554.80 1,238.30 1,212.20 1,169.80 1,162.90 1,266.00 740.70 Power & Fuel Cost - 93.10 88.90 81.90 76.40 59.40 62.40 59.60 56.10 50.50 43.70 % Of Sales - 2.27% 2.49% 3.48% 4.32% 3.59% 3.49% 3.00% 2.68% 2.58% 4.28% Employee Cost - 515.30 454.90 425.70 410.10 380.00 356.10 340.20 312.20 232.10 171.90 % Of Sales - 12.59% 12.75% 18.11% 23.20% 22.98% 19.89% 17.13% 14.93% 11.85% 16.83% Manufacturing Exp. - 357.70 341.70 269.90 340.80 160.50 230.40 257.50 175.10 162.70 100.60 % Of Sales - 8.74% 9.57% 11.48% 19.28% 9.71% 12.87% 12.96% 8.37% 8.31% 9.85% General & Admin Exp. - 246.80 253.10 155.70 122.50 92.60 111.20 103.90 96.00 78.30 56.90 % Of Sales - 6.03% 7.09% 6.62% 6.93% 5.60% 6.21% 5.23% 4.59% 4.00% 5.57% Selling & Distn. Exp. - 105.60 117.40 59.50 27.00 29.20 22.60 33.50 98.00 128.80 88.40 % Of Sales - 2.58% 3.29% 2.53% 1.53% 1.77% 1.26% 1.69% 4.69% 6.58% 8.65% Miscellaneous Exp. - 88.90 150.10 51.90 75.90 44.30 59.70 57.50 37.00 40.80 88.40 % Of Sales - 2.17% 4.21% 2.21% 4.29% 2.68% 3.33% 2.89% 1.77% 2.08% 2.24% EBITDA 1,304.90 2,142.10 1,637.00 820.80 213.00 415.20 578.00 816.50 928.40 692.00 280.70 EBITDA Margin 36.30% 52.32% 45.87% 34.91% 12.05% 25.11% 32.29% 41.11% 44.39% 35.34% 27.48% Other Income 281.10 323.50 104.70 109.40 94.60 103.50 123.80 129.80 39.40 13.20 12.90 Interest 32.30 19.60 14.50 8.60 13.30 11.30 20.60 18.80 14.70 17.50 21.90 Depreciation 189.60 220.00 171.90 150.90 138.40 115.20 98.10 80.10 65.50 53.60 50.20 PBT 1,364.10 2,226.00 1,555.30 770.70 155.90 392.20 583.10 847.40 887.60 634.10 221.50 Tax 82.60 375.60 248.70 133.60 16.80 82.70 108.60 180.30 189.40 139.30 45.00 Tax Rate 6.06% 16.87% 15.99% 17.33% 10.78% 21.09% 18.62% 21.28% 21.34% 21.97% 20.32% PAT 1,281.50 1,850.40 1,306.60 637.10 139.10 309.50 474.50 667.10 698.20 494.80 176.50 PAT before Minority Interest 1,281.50 1,850.40 1,306.60 637.10 139.10 309.50 474.50 667.10 698.20 494.80 176.50 Minority Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT Margin 35.65% 45.19% 36.61% 27.10% 7.87% 18.72% 26.51% 33.59% 33.39% 25.27% 17.28% PAT Growth -30.74% 41.62% 105.09% 358.02% -55.06% -34.77% -28.87% -4.45% 41.11% 180.34% EPS 71.55 103.32 72.95 35.57 7.77 17.28 26.49 37.25 38.98 27.63 9.85

Description TTM Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Net Sales 4,078.30 4,429.50 3,998.80 2,707.10 1,944.80 2,052.10 1,915.00 2,094.50 2,184.80 2,020.20 1,042.30 Net Sales Growth -7.93% 10.77% 47.72% 39.20% -5.23% 7.16% -8.57% -4.13% 8.15% 93.82% Cost Of Goods Sold 690.50 641.50 667.90 583.20 528.40 483.70 354.40 332.70 411.10 599.10 270.60 Gross Profit 3,387.80 3,788.00 3,330.90 2,123.90 1,416.40 1,568.40 1,560.60 1,761.80 1,773.70 1,421.10 771.70 GP Margin 83.07% 85.52% 83.30% 78.46% 72.83% 76.43% 81.49% 84.12% 81.18% 70.34% 74.04% Total Expenditure 2,641.80 2,235.70 2,247.40 1,795.40 1,681.30 1,448.30 1,332.40 1,299.70 1,256.40 1,336.80 776.70 Power & Fuel Cost - 93.10 88.90 81.90 76.40 61.10 62.40 59.60 56.20 50.50 43.70 % Of Sales - 2.10% 2.22% 3.03% 3.93% 2.98% 3.26% 2.85% 2.57% 2.50% 4.19% Employee Cost - 594.50 525.00 486.70 444.80 414.90 375.00 355.90 325.60 243.20 179.80 % Of Sales - 13.42% 13.13% 17.98% 22.87% 20.22% 19.58% 16.99% 14.90% 12.04% 17.25% Manufacturing Exp. - 374.80 368.40 279.60 353.60 291.90 243.30 276.40 182.60 169.70 105.20 % Of Sales - 8.46% 9.21% 10.33% 18.18% 14.22% 12.70% 13.20% 8.36% 8.40% 10.09% General & Admin Exp. - 304.00 313.00 208.80 152.80 116.70 132.60 126.40 105.50 88.10 61.70 % Of Sales - 6.86% 7.83% 7.71% 7.86% 5.69% 6.92% 6.03% 4.83% 4.36% 5.92% Selling & Distn. Exp. - 136.40 153.00 96.10 43.70 34.40 98.10 90.00 136.90 143.20 91.60 % Of Sales - 3.08% 3.83% 3.55% 2.25% 1.68% 5.12% 4.30% 6.27% 7.09% 8.79% Miscellaneous Exp. - 91.40 131.20 59.10 81.60 45.60 66.60 58.70 38.50 43.00 91.60 % Of Sales - 2.06% 3.28% 2.18% 4.20% 2.22% 3.48% 2.80% 1.76% 2.13% 2.31% EBITDA 1,436.50 2,193.80 1,751.40 911.70 263.50 603.80 582.60 794.80 928.40 683.40 265.60 EBITDA Margin 35.22% 49.53% 43.80% 33.68% 13.55% 29.42% 30.42% 37.95% 42.49% 33.83% 25.48% Other Income 297.60 356.70 128.10 128.50 99.00 106.00 107.40 130.20 40.40 13.90 9.60 Interest 36.70 23.90 19.20 14.50 17.70 13.30 21.50 19.30 15.40 18.50 22.90 Depreciation 206.60 235.20 186.80 163.80 142.60 116.90 99.80 81.00 66.20 54.40 50.80 PBT 1,490.80 2,291.40 1,673.50 861.90 202.20 579.60 568.70 824.70 887.20 624.40 201.50 Tax 118.90 408.00 285.20 146.60 32.20 137.20 110.60 182.30 192.00 139.50 47.90 Tax Rate 7.98% 17.81% 17.04% 17.01% 15.92% 23.67% 19.45% 22.11% 21.64% 22.34% 23.77% PAT 1,371.90 1,885.40 1,388.30 715.30 170.00 440.90 460.80 644.40 696.20 486.00 154.90 PAT before Minority Interest 1,371.90 1,883.40 1,388.30 715.30 170.00 442.40 458.10 642.40 695.20 484.90 153.60 Minority Interest 0.00 2.00 0.00 0.00 0.00 -1.50 2.70 2.00 1.00 1.10 1.30 PAT Margin 33.64% 42.56% 34.72% 26.42% 8.74% 21.49% 24.06% 30.77% 31.87% 24.06% 14.86% PAT Growth -27.16% 35.81% 94.09% 320.76% -61.44% -4.32% -28.49% -7.44% 43.25% 213.75% EPS 76.60 105.27 77.52 39.94 9.49 24.62 25.73 35.98 38.87 27.14 8.65

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Shareholder's Funds 7,333.90 5,592.30 4,702.00 4,191.90 4,091.10 3,869.50 3,563.20 3,125.40 1,699.70 1,336.30 Share Capital 35.80 35.80 36.50 36.50 36.50 36.40 36.50 36.90 34.90 34.80 Total Reserves 7,298.10 5,556.50 4,665.50 4,152.00 4,037.00 3,809.50 3,495.80 3,064.30 1,649.40 1,291.80 Non-Current Liabilities 30.40 69.00 116.90 134.90 142.90 117.50 83.10 47.00 37.70 27.90 Secured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Unsecured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Long Term Provisions 65.60 70.90 85.30 95.70 99.60 90.20 71.00 32.40 21.90 12.50 Current Liabilities 864.60 885.60 569.00 651.20 518.50 659.70 709.80 563.80 609.70 478.50 Trade Payables 225.10 183.30 182.40 141.20 139.50 234.20 201.80 245.40 251.40 270.10 Other Current Liabilities 210.70 204.70 201.40 104.00 111.10 94.20 108.50 131.70 122.80 110.90 Short Term Borrowings 273.10 363.20 159.90 389.00 255.10 312.30 384.50 173.00 220.60 96.00 Short Term Provisions 155.70 134.40 25.30 17.00 12.80 19.00 15.00 13.70 14.90 1.50 Total Liabilities 8,228.90 6,546.90 5,387.90 4,978.00 4,752.50 4,646.70 4,356.10 3,736.20 2,347.10 1,842.70 Net Block 2,516.80 2,286.70 2,233.80 2,174.20 2,005.90 1,574.50 1,214.90 1,015.30 829.00 705.60 Gross Block 3,783.70 3,359.50 3,157.10 2,977.80 2,678.30 2,133.70 1,678.20 1,399.60 1,151.00 975.90 Accumulated Depreciation 1,216.90 1,072.80 923.30 803.60 672.40 559.20 463.30 384.30 322.00 270.30 Non Current Assets 3,540.90 3,136.50 2,893.20 2,810.30 2,584.00 2,406.80 2,088.70 1,682.00 1,312.00 1,051.80 Capital Work in Progress 225.30 133.90 62.80 128.70 223.40 517.80 637.50 480.00 336.20 211.90 Non Current Investment 565.10 577.80 517.60 430.40 294.90 186.10 117.60 101.30 85.90 71.70 Long Term Loans & Adv. 73.00 111.50 78.80 72.40 55.60 124.30 110.40 77.40 54.90 58.40 Other Non Current Assets 160.70 26.60 0.20 4.60 4.20 4.10 8.30 8.00 6.00 4.20 Current Assets 4,688.00 3,410.40 2,494.70 2,167.70 2,168.50 2,239.90 2,267.40 2,054.20 1,035.10 790.90 Current Investments 290.00 163.90 139.90 119.60 42.10 5.00 126.80 48.30 8.90 22.10 Inventories 642.10 596.90 616.00 697.70 769.20 524.40 508.40 425.80 336.90 351.90 Sundry Debtors 1,178.20 1,076.60 793.10 575.60 399.80 536.70 491.60 606.00 468.90 255.80 Cash & Bank 1,856.90 864.90 412.00 100.90 262.80 54.10 262.70 172.10 25.10 40.20 Other Current Assets 720.80 86.10 57.60 78.10 694.60 1,119.70 877.90 802.00 195.30 120.90 Short Term Loans & Adv. 597.40 622.00 476.10 595.80 599.40 1,025.90 769.50 748.80 169.60 95.50 Net Current Assets 3,823.40 2,524.80 1,925.70 1,516.50 1,650.00 1,580.20 1,557.60 1,490.40 425.40 312.40 Total Assets 8,228.90 6,546.90 5,387.90 4,978.00 4,752.50 4,646.70 4,356.10 3,736.20 2,347.10 1,842.70

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Shareholder's Funds 7,607.00 5,853.10 4,873.80 4,263.60 4,121.60 3,773.50 3,489.00 3,072.20 1,649.30 1,295.70 Share Capital 35.80 35.80 36.50 36.50 36.50 36.40 36.50 36.90 34.90 34.80 Total Reserves 7,571.20 5,817.30 4,837.30 4,223.70 4,067.60 3,713.60 3,421.70 3,011.40 1,599.00 1,251.20 Non-Current Liabilities 24.90 61.00 100.50 135.10 142.90 117.80 83.40 47.10 37.70 28.00 Secured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Unsecured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Long Term Provisions 65.60 70.90 85.30 95.70 99.60 90.20 71.00 32.40 21.90 12.50 Current Liabilities 943.50 972.80 683.10 710.40 525.60 685.30 728.70 592.00 626.50 493.10 Trade Payables 274.90 235.50 263.80 161.80 146.20 255.40 217.00 269.10 262.70 275.60 Other Current Liabilities 238.60 238.90 227.30 126.70 99.50 96.70 109.80 133.40 127.10 114.20 Short Term Borrowings 273.10 363.20 165.00 404.00 265.80 314.20 386.30 173.20 221.60 98.40 Short Term Provisions 156.90 135.20 27.00 17.90 14.10 19.00 15.60 16.30 15.10 4.90 Total Liabilities 8,580.70 6,886.90 5,657.40 5,109.10 4,791.90 4,587.80 4,303.10 3,715.10 2,317.60 1,821.70 Net Block 2,698.00 2,490.80 2,426.90 2,311.80 2,023.20 1,584.40 1,227.20 1,018.60 833.00 710.10 Gross Block 4,015.20 3,603.20 3,375.10 3,126.90 2,702.10 2,148.70 1,694.50 1,407.60 1,158.70 983.30 Accumulated Depreciation 1,267.20 1,112.40 948.20 815.10 678.90 564.30 467.30 389.00 325.70 273.20 Non Current Assets 3,310.70 2,863.40 2,657.10 2,622.40 2,447.10 2,262.20 1,955.90 1,584.40 1,230.30 984.70 Capital Work in Progress 225.40 137.30 64.30 129.50 223.40 518.00 637.60 480.00 336.30 211.80 Non Current Investment 152.80 95.90 87.30 104.40 151.90 83.60 19.90 8.10 0.10 0.10 Long Term Loans & Adv. 73.80 112.70 78.30 72.00 44.30 72.00 62.80 69.60 54.90 58.50 Other Non Current Assets 160.70 26.70 0.30 4.70 4.30 4.20 8.40 8.10 6.00 4.20 Current Assets 5,270.00 4,023.50 3,000.30 2,486.70 2,344.80 2,325.60 2,347.20 2,130.70 1,087.30 837.00 Current Investments 320.80 443.50 305.00 203.70 151.80 28.70 148.70 68.40 32.10 22.10 Inventories 765.80 700.50 742.90 762.00 798.20 558.00 529.00 438.40 348.90 357.30 Sundry Debtors 1,246.60 1,188.90 856.10 620.60 412.90 551.30 506.20 637.50 475.20 261.60 Cash & Bank 2,176.00 952.90 546.30 206.10 283.50 66.00 279.50 183.70 35.80 45.20 Other Current Assets 760.80 99.50 64.40 88.10 698.40 1,121.60 883.80 802.70 195.30 150.80 Short Term Loans & Adv. 625.70 638.20 485.60 606.20 603.70 1,030.00 776.40 749.50 169.50 125.40 Net Current Assets 4,326.50 3,050.70 2,317.20 1,776.30 1,819.20 1,640.30 1,618.50 1,538.70 460.80 343.90 Total Assets 8,580.70 6,886.90 5,657.40 5,109.10 4,791.90 4,587.80 4,303.10 3,715.10 2,317.60 1,821.70

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Cash From Operating Activity 1,662.00 1,196.40 784.40 57.70 183.50 422.50 698.80 476.40 329.80 189.90 PBT 2,226.00 1,555.30 770.70 155.90 392.20 583.10 847.40 887.60 634.10 221.50 Adjustment -20.40 150.90 85.40 118.50 58.40 45.20 12.10 74.40 99.80 81.70 Changes in Working Capital -199.00 -257.80 76.70 -184.20 -190.20 -100.70 14.20 -281.20 -281.70 -68.50 Cash after chg. in Working capital 2,006.60 1,448.40 932.80 90.20 260.40 527.60 873.70 680.80 452.20 234.70 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid -344.60 -252.00 -148.40 -32.50 -76.90 -105.10 -174.90 -204.40 -122.40 -44.80 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity -1,443.90 -960.50 -436.60 -92.50 -3.20 -165.00 -645.20 -1,131.10 -290.60 -249.30 Net Fixed Assets -515.60 -273.50 -113.40 -204.80 -250.20 -335.80 -436.10 -392.40 -299.40 -303.91 Net Investments -113.40 -84.20 -107.50 -213.00 -145.90 53.30 -94.80 -54.80 -1.00 37.47 Others -814.90 -602.80 -215.70 325.30 392.90 117.50 -114.30 -683.90 9.80 17.14 Cash from Financing Activity -212.40 -237.30 -346.80 35.60 -183.10 -261.10 -52.20 652.00 -45.60 151.40 Net Cash Inflow / Outflow 5.70 -1.40 1.00 0.80 -2.80 -3.60 1.40 -2.70 -6.40 92.00 Opening Cash & Equivalents 5.50 6.90 5.90 5.10 7.90 11.50 10.10 12.80 19.20 -170.00 Closing Cash & Equivalent 11.20 5.50 6.90 5.90 5.10 7.90 11.50 10.10 12.80 -76.80

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Cash From Operating Activity 1,696.80 1,211.60 849.10 46.50 298.80 417.30 668.80 463.60 345.80 112.20 PBT 2,291.40 1,673.50 861.90 202.20 579.60 568.70 824.70 887.20 624.40 208.60 Adjustment -22.30 133.80 102.00 123.90 62.10 54.00 14.30 75.60 100.20 90.50 Changes in Working Capital -199.70 -309.40 62.70 -231.40 -212.90 -97.60 8.60 -294.60 -253.00 -140.70 Cash after chg. in Working capital 2,069.40 1,497.90 1,026.60 94.70 428.80 525.10 847.60 668.20 471.60 158.40 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid -372.60 -286.30 -177.50 -48.20 -130.00 -107.80 -178.80 -204.60 -125.80 -46.20 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity -1,414.50 -1,032.70 -477.10 -5.30 -103.30 -167.00 -612.20 -1,115.50 -299.40 -175.50 Net Fixed Assets -515.60 -273.50 -113.40 -204.80 -250.20 -335.80 -436.10 -392.40 -299.40 -303.91 Net Investments -113.40 -84.20 -107.50 -213.00 -145.90 53.30 -94.80 -54.80 -1.00 37.47 Others -785.50 -675.00 -256.20 412.50 292.80 115.50 -81.30 -668.30 1.00 90.94 Cash from Financing Activity -210.70 -246.90 -363.00 34.80 -185.70 -250.80 -50.90 650.90 -47.70 154.00 Net Cash Inflow / Outflow 71.60 -68.00 9.00 76.00 9.80 -0.50 5.70 -1.00 -1.30 90.70 Opening Cash & Equivalents 70.40 131.90 111.10 25.80 19.80 28.30 21.70 23.50 24.20 -164.10 Closing Cash & Equivalent 120.00 70.40 131.90 111.10 25.80 19.80 28.30 21.70 23.50 -74.20

Financial Ratios

Consolidated /

Standalone

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Book Value (Rs.) 409.72 312.42 257.64 229.51 223.21 211.31 193.55 168.09 96.52 76.24 ROA 25.05% 21.90% 12.29% 2.86% 6.59% 10.54% 16.49% 22.95% 23.62% 10.90% ROE 28.63% 25.38% 14.33% 3.37% 7.82% 12.86% 20.11% 29.18% 32.87% 16.00% ROCE 33.11% 29.02% 16.51% 3.79% 9.46% 14.85% 23.91% 34.58% 38.71% 18.48% Fixed Asset Turnover 1.19 1.15 0.78 0.65 0.70 0.99 1.41 1.65 1.88 1.20 Receivable days 97.17 90.80 104.18 96.61 101.41 99.38 92.04 93.04 66.04 76.63 Inventory Days 53.39 58.90 100.00 145.29 140.07 99.81 78.34 66.02 62.77 94.81 Payable days 136.76 126.93 121.62 102.03 144.40 66.65 73.69 81.82 79.78 95.04 Cash Conversion Cycle 13.80 22.77 82.56 139.87 97.08 132.54 96.69 77.23 49.02 76.39 Total Debt/Equity 0.04 0.06 0.03 0.09 0.06 0.08 0.11 0.06 0.13 0.08 Interest Cover 114.57 108.26 90.62 12.72 35.71 29.31 46.07 61.38 37.23 11.11

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16
Book Value (Rs.) 424.97 326.99 267.06 233.44 224.88 206.04 189.49 165.22 93.63 73.91 ROA 24.35% 22.13% 13.29% 3.43% 9.43% 10.30% 16.02% 23.05% 23.43% 9.72% ROE 27.98% 25.88% 15.66% 4.06% 11.27% 12.71% 19.75% 29.70% 33.21% 14.62% ROCE 32.85% 30.08% 18.06% 4.86% 13.99% 14.82% 23.71% 35.28% 39.21% 18.04% Fixed Asset Turnover 1.25 1.24 0.89 0.76 0.86 1.07 1.47 1.72 1.93 1.23 Receivable days 93.30 86.16 93.53 85.10 84.44 93.77 91.36 92.22 65.12 70.27 Inventory Days 56.17 60.81 95.32 128.47 118.77 96.38 77.28 65.25 62.41 89.35 Payable days 145.20 136.43 133.18 106.38 151.52 65.96 72.53 81.42 78.30 85.42 Cash Conversion Cycle 4.27 10.54 55.67 107.20 51.68 124.19 96.11 76.05 49.23 74.21 Total Debt/Equity 0.04 0.06 0.03 0.09 0.06 0.08 0.11 0.06 0.14 0.09 Interest Cover 96.87 88.16 60.44 12.42 44.58 27.45 43.73 58.61 34.75 10.11

Top Investors:

belgrave investment fund

life insurance corportion of india

akash bhanshali

investor education and protection fund (iepf)

llp

Annual Reports:

News Update:

Natco Pharma, Lupin receive USFDA’s approval for Eribulin Mesylate Injection
3rd Jun 2026, 12:29 PM

Eribulin Mesylate Injection, 1 mg/2 mL Single-Dose Vials is the bioequivalent to the RLD Halaven Injection of Eisai, Inc
Read More
Natco Pharma reports 34% fall in Q4 consolidated net profit
30th May 2026, 15:00 PM

Consolidated total income of the company decreased by 36.54% at Rs 816.90 crore for Q4FY26
Read More
Natco Pharma - Quarterly Results
30th May 2026, 00:00 AM

Read More

Natco Pharma Ltd.

Pharmaceuticals & Drugs - Global

BSE: 524816 | NSE: NATCOPHARM

Stock Summary

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Earnings Forecasts:

Quarterly Results

Consolidated Figures in Rs. Crores /

Annual Results

Consolidated Figures in Rs. Crores /

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Cash Flow

Consolidated Figures in Rs. Crores /

Financial Ratios

Consolidated /

Top Investors:

Annual Reports:

News Update:

Natco Pharma Ltd.

Pharmaceuticals & Drugs - Global

BSE: 524816 | NSE: NATCOPHARM

Stock Summary

Shareholding Pattern

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Earnings Forecasts:

Quarterly Results

Consolidated Figures in Rs. Crores /

Annual Results

Consolidated Figures in Rs. Crores /

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Cash Flow

Consolidated Figures in Rs. Crores /

Financial Ratios

Consolidated /

Top Investors:

Annual Reports:

News Update: